The use of sequential living donor kidney and autologous stem cell transplantation for patients with primary (Al) amyloidosis and advanced renal failure

N. Leung, M. D. Griffin, Angela Dispenzieri, J. M. Gloor, T. R. Schwab, Stephen C Textor, Martha Lacy, T. S. Larson, Mark D Stegall, Morie Gertz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients with primary (AL) amyloidosis and renal failure have limited life expectancy on dialysis and face higher risk during autologous stem cell transplantation (ASCT). We have pursued a novel strategy of living donor kidney transplant (KTx) prior to ASCT for these patients. Clinical and laboratory outcomes of all 7 patients accepted for this protocol at Mayo Clinic between Dec 1999 and Feb 2003 were reviewed. Five of the 7 were on dialysis prior to KTx. All 7 patients underwent living donor KTx and experienced good initial graft function. Immunosuppression was tacrolimus (n = 4), cyclosporine (n = 2), or sirolimus (n = 1) in combination with mycophenolate mofetil and prednisone. Five patients subsequently underwent ASCT, 4 with good outcome. For these 4 patients, stem cell harvest was carried out prior to KTx for 3 and after KTx for 1. Average times to neutrophil and platelet engraftment were 15.5 and 23.5 days respectively. The fifth developed progressive hepatic amyloidosis after KTx and was advised against ASCT, died following ASCT elsewhere. Two did not undergo ASCT. One died of a demyelinating disease 4 weeks after KTx. The other has thus far elected not to undergo ASCT and has minimal recurrent disease after 3 years. Living donor KTx followed by ASCT is a feasible approach for AL patients with advanced renal impairment. Prudent patient selection is crucial as KTx will delay ASCT. Stem cell engraftment was not impaired by triple-drug immunosuppression.

Original languageEnglish (US)
Title of host publicationAmyloid and Amyloidosis
PublisherCRC Press
Pages127-129
Number of pages3
ISBN (Electronic)9781420037494
ISBN (Print)0849335345, 9780849335341
StatePublished - Jan 1 2004

Fingerprint

Living Donors
Stem Cell Transplantation
Renal Insufficiency
Kidney
Immunosuppression
Dialysis
Stem Cells
Mycophenolic Acid
Transplants
Primary amyloidosis
Demyelinating Diseases
Tacrolimus
Amyloidosis
Sirolimus
Prednisone
Life Expectancy
Patient Selection
Cyclosporine
Neutrophils
Blood Platelets

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

The use of sequential living donor kidney and autologous stem cell transplantation for patients with primary (Al) amyloidosis and advanced renal failure. / Leung, N.; Griffin, M. D.; Dispenzieri, Angela; Gloor, J. M.; Schwab, T. R.; Textor, Stephen C; Lacy, Martha; Larson, T. S.; Stegall, Mark D; Gertz, Morie.

Amyloid and Amyloidosis. CRC Press, 2004. p. 127-129.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{66333077a2184e5ebe8d6305e5aaa9a6,
title = "The use of sequential living donor kidney and autologous stem cell transplantation for patients with primary (Al) amyloidosis and advanced renal failure",
abstract = "Patients with primary (AL) amyloidosis and renal failure have limited life expectancy on dialysis and face higher risk during autologous stem cell transplantation (ASCT). We have pursued a novel strategy of living donor kidney transplant (KTx) prior to ASCT for these patients. Clinical and laboratory outcomes of all 7 patients accepted for this protocol at Mayo Clinic between Dec 1999 and Feb 2003 were reviewed. Five of the 7 were on dialysis prior to KTx. All 7 patients underwent living donor KTx and experienced good initial graft function. Immunosuppression was tacrolimus (n = 4), cyclosporine (n = 2), or sirolimus (n = 1) in combination with mycophenolate mofetil and prednisone. Five patients subsequently underwent ASCT, 4 with good outcome. For these 4 patients, stem cell harvest was carried out prior to KTx for 3 and after KTx for 1. Average times to neutrophil and platelet engraftment were 15.5 and 23.5 days respectively. The fifth developed progressive hepatic amyloidosis after KTx and was advised against ASCT, died following ASCT elsewhere. Two did not undergo ASCT. One died of a demyelinating disease 4 weeks after KTx. The other has thus far elected not to undergo ASCT and has minimal recurrent disease after 3 years. Living donor KTx followed by ASCT is a feasible approach for AL patients with advanced renal impairment. Prudent patient selection is crucial as KTx will delay ASCT. Stem cell engraftment was not impaired by triple-drug immunosuppression.",
author = "N. Leung and Griffin, {M. D.} and Angela Dispenzieri and Gloor, {J. M.} and Schwab, {T. R.} and Textor, {Stephen C} and Martha Lacy and Larson, {T. S.} and Stegall, {Mark D} and Morie Gertz",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "0849335345",
pages = "127--129",
booktitle = "Amyloid and Amyloidosis",
publisher = "CRC Press",

}

TY - CHAP

T1 - The use of sequential living donor kidney and autologous stem cell transplantation for patients with primary (Al) amyloidosis and advanced renal failure

AU - Leung, N.

AU - Griffin, M. D.

AU - Dispenzieri, Angela

AU - Gloor, J. M.

AU - Schwab, T. R.

AU - Textor, Stephen C

AU - Lacy, Martha

AU - Larson, T. S.

AU - Stegall, Mark D

AU - Gertz, Morie

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Patients with primary (AL) amyloidosis and renal failure have limited life expectancy on dialysis and face higher risk during autologous stem cell transplantation (ASCT). We have pursued a novel strategy of living donor kidney transplant (KTx) prior to ASCT for these patients. Clinical and laboratory outcomes of all 7 patients accepted for this protocol at Mayo Clinic between Dec 1999 and Feb 2003 were reviewed. Five of the 7 were on dialysis prior to KTx. All 7 patients underwent living donor KTx and experienced good initial graft function. Immunosuppression was tacrolimus (n = 4), cyclosporine (n = 2), or sirolimus (n = 1) in combination with mycophenolate mofetil and prednisone. Five patients subsequently underwent ASCT, 4 with good outcome. For these 4 patients, stem cell harvest was carried out prior to KTx for 3 and after KTx for 1. Average times to neutrophil and platelet engraftment were 15.5 and 23.5 days respectively. The fifth developed progressive hepatic amyloidosis after KTx and was advised against ASCT, died following ASCT elsewhere. Two did not undergo ASCT. One died of a demyelinating disease 4 weeks after KTx. The other has thus far elected not to undergo ASCT and has minimal recurrent disease after 3 years. Living donor KTx followed by ASCT is a feasible approach for AL patients with advanced renal impairment. Prudent patient selection is crucial as KTx will delay ASCT. Stem cell engraftment was not impaired by triple-drug immunosuppression.

AB - Patients with primary (AL) amyloidosis and renal failure have limited life expectancy on dialysis and face higher risk during autologous stem cell transplantation (ASCT). We have pursued a novel strategy of living donor kidney transplant (KTx) prior to ASCT for these patients. Clinical and laboratory outcomes of all 7 patients accepted for this protocol at Mayo Clinic between Dec 1999 and Feb 2003 were reviewed. Five of the 7 were on dialysis prior to KTx. All 7 patients underwent living donor KTx and experienced good initial graft function. Immunosuppression was tacrolimus (n = 4), cyclosporine (n = 2), or sirolimus (n = 1) in combination with mycophenolate mofetil and prednisone. Five patients subsequently underwent ASCT, 4 with good outcome. For these 4 patients, stem cell harvest was carried out prior to KTx for 3 and after KTx for 1. Average times to neutrophil and platelet engraftment were 15.5 and 23.5 days respectively. The fifth developed progressive hepatic amyloidosis after KTx and was advised against ASCT, died following ASCT elsewhere. Two did not undergo ASCT. One died of a demyelinating disease 4 weeks after KTx. The other has thus far elected not to undergo ASCT and has minimal recurrent disease after 3 years. Living donor KTx followed by ASCT is a feasible approach for AL patients with advanced renal impairment. Prudent patient selection is crucial as KTx will delay ASCT. Stem cell engraftment was not impaired by triple-drug immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=85057691178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057691178&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057691178

SN - 0849335345

SN - 9780849335341

SP - 127

EP - 129

BT - Amyloid and Amyloidosis

PB - CRC Press

ER -